Al Hayek Ayman, Al Dawish Mohamed, El Jammal Manal
Department of Endocrinology and Diabetes, Prince Sultan Military Medical City, Riyadh, SAU.
Scientific Affairs, Abbott Diabetes Care, Dubai, ARE.
Cureus. 2021 Jun 28;13(6):e16007. doi: 10.7759/cureus.16007. eCollection 2021 Jun.
The effect of flash glucose monitoring on glycaemic control and patient satisfaction in insulin-treated type 2 diabetes (T2D) from Saudi Arabia is uncertain. The aim of this prospective observational study was to evaluate the change in HbA1c (Hemoglobin A1c) and satisfaction with treatment following the initiation of flash glucose monitoring.
This single-arm, single-centre prospective observational study included flash glucose monitoring-naive adult patients with T2D managed with multiple daily injections of insulin therapy (MDI) and HbA1c ≥7%. HbA1c was measured, and the Diabetes Treatment Satisfaction Questionnaire (DTSQ, Arabic version) and Glucose Monitoring Satisfaction Survey (GMSS) were completed at baseline and 12 weeks.
For participants (n=54) from one diabetes centre, HbA1c significantly improved by 0.44% from 8.22%±0.69 (mean±SD) at baseline to 7.78%±0.71 at 12 weeks, p<0.001. Confirmed hypoglycaemic episodes reduced from 4.43±1.51 episodes/month to 1.24±1.15 (-3.19, p<0.001). Glucose monitoring frequency improved, indicated by the number of scans per day, with a mean increase of 5.13 (p <0.001) tests/day. GMSS scores improved across all four categories, as did overall treatment satisfaction (p<0.001 for all categories). Patients perceived clear improvements across all questions relating to satisfaction and frequency of hypo- or hyperglycaemic episodes.
Following initiation of flash glucose monitoring in patients with T2D and MDI insulin therapy, HbA1c improved with reduced hypoglycaemic events and increased patient-reported satisfaction. This study contributes valuable data on the use of flash glucose monitoring in this population, and a larger multicentre study is warranted to inform future health policy for T2D in Saudi Arabia.
在沙特阿拉伯，即时血糖监测对接受胰岛素治疗的2型糖尿病（T2D）患者血糖控制及患者满意度的影响尚不确定。这项前瞻性观察性研究的目的是评估启动即时血糖监测后糖化血红蛋白（HbA1c）的变化以及对治疗的满意度。
这项单臂、单中心前瞻性观察性研究纳入了未使用过即时血糖监测的成年T2D患者，这些患者采用每日多次胰岛素注射治疗（MDI）且HbA1c≥7%。在基线和12周时测量HbA1c，并完成糖尿病治疗满意度问卷（DTSQ，阿拉伯语版）和血糖监测满意度调查（GMSS）。
来自一个糖尿病中心的参与者（n = 54），HbA1c从基线时的8.22%±0.69（均值±标准差）显著改善至12周时的7.78%±0.71，改善了0.44%，p<0.001。确诊的低血糖发作次数从每月4.43±1.51次降至1.24±1.15次（-3.19，p<0.001）。以每日扫描次数表示的血糖监测频率有所提高，平均每天增加5.13次检测（p <0.001）。GMSS评分在所有四个类别中均有所改善，总体治疗满意度也有所提高（所有类别p<0.001）。患者在与低血糖或高血糖发作的满意度和频率相关的所有问题上都明显感觉有改善。
在接受MDI胰岛素治疗的T2D患者中启动即时血糖监测后，HbA1c得到改善，低血糖事件减少，患者报告的满意度提高。本研究为该人群使用即时血糖监测提供了有价值的数据，有必要开展更大规模的多中心研究，为沙特阿拉伯未来的T2D健康政策提供参考。
